Hormonal
Oral semaglutide is associated with a significantly lower risk of incident atrial fibrillation (AF), while dulaglutide shows an increasing trend toward higher AF risk compared to controls.
Among GLP-1 medications, oral semaglutide (Rybelsus) may actually lower the risk of atrial fibrillation, while dulaglutide (Trulicity) might slightly increase it. This difference is drug-specific and not seen with all GLP-1s. If you have a history of AF, discuss the specific drug choice with your doctor.
In further subgroup analyses, we observed an increasing trend toward incident AF with dulaglutide (RR 1.40, 95% CI 1.03–1.90) while an inverse trend with oral semaglutide (RR 0.43, 95% CI 0.21–0.87).
Why this rating
Meta-analysis of RCTs, but sensitivity analysis showed significance was driven by specific large trials (REWIND, PIONEER-6).
Source
Association of glucagon-like peptide-1 receptor agonists with cardiac arrhythmias in patients with type 2 diabetes or obesity: a systematic review and meta-analysis of randomized controlled trials
Sijin Wu et al. · Diabetology & Metabolic Syndrome · 2022
DOI 10.1186/s13098-022-00970-2
More from this paper
- GLP-1 receptor agonists do not significantly increase the overall risk of cardiac arrhythmias (atrial fibrillation, atrial flutter, ventricular arrhythmias, or sudden cardiac death) in patients with type 2 diabetes or obesity compared to controls.Strong
- High-dose GLP-1 receptor agonists and treatment of patients with higher baseline BMI are associated with a significantly increased risk of ventricular arrhythmias (VAs).Good
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →